Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Bone Marrow Sinusoidal Integrity Regulates Hematopoietic Stem and Progenitor Cell Trafficking

Pratibha Singh, PhD, Khalid Mohammad, PhD, Jonathan Hoggatt, PhD, Jennifer M. Speth, PhD, Louis M. Pelus, PhD

Blood (2013) 122 (21): 3687.

https://doi.org/10.1182/blood.V122.21.3687.3687

Published: 2013

Journal Articles

DPP4 (CD26) Truncation Of GM-CSF and IL-3 Alters Their Signaling and Functional Activity In Normal and Leukemic Hematopoietic Stem and Progenitor Cells

Heather A. O'Leary, Ph.D., Charlie Mantel, Xianyin Lai, Ph.D., Scott Cooper, BS, Giao Hangoc, DVM, Ph.D., H. Scott Boswell, M.D., Frank Witzmann, Ph.D., Hal E. Broxmeyer, PhD

Blood (2013) 122 (21): 1206.

https://doi.org/10.1182/blood.V122.21.1206.1206

Published: 2013

Journal Articles

Sinusoidal Endothelial CD26 Cleavage of Neuropeptide Y Regulates Transendothelial Migration and Mobilization of Hematopoietic Stem and Progenitor Cells in Response to G-CSF.

Pratibha Singh, PhD, Jonathan Hoggatt, Ph.D., Peirong Hu, PhD, Louis M. Pelus, PhD

Blood (2012) 120 (21): 2347.

https://doi.org/10.1182/blood.V120.21.2347.2347

Published: 2012

Journal Articles

CD26 Truncation of GM-CSF and IL-3 Alters Their Functional Interactions

Heather A. O'Leary, PhD, Charlie Mantel, Scott Cooper, BS, Christina J Walker, BS, Hal E. Broxmeyer, Ph.D.

Blood (2012) 120 (21): 1240.

https://doi.org/10.1182/blood.V120.21.1240.1240

Published: 2012

Journal Articles

Dipeptidyl Peptidase Inhibition Alters Myeloid Derived Suppressor Cell Phenotype and Induces Regression of Pediatric Sarcomas.

Najat Bouchkouj, MD, Shannon Larabee, Haying Qin, Joanna Louise Meadors, BS, Crystal L Mackall, MD, Terry J Fry, MD

Blood (2010) 116 (21): 3792.

https://doi.org/10.1182/blood.V116.21.3792.3792

Published: 2010

Journal Articles

ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL).

Alexey V. Danilov, MD, PhD, Olga Danilova, MD, PhD, Andreas Klein, MD, Jennifer Brown, MD, PhD, Arthur P. Rabinowitz, MD, Kenneth B Miller, MD, Brigitte T Huber, PhD

Blood (2009) 114 (22): 1251.

https://doi.org/10.1182/blood.V114.22.1251.1251

Published: 2009

Journal Articles

Differential Protein Expression of Serum in Patients with RAEB Myelodysplastic Syndromes.

Liye Zhong, Tianhao Liu, Yangqiu Li, PhD, Suxia Geng, Zesheng Lu, Jianyu Weng, Suijing Wu, Xin Du, PhD

Blood (2009) 114 (22): 4845.

https://doi.org/10.1182/blood.V114.22.4845.4845

Published: 2009

Journal Articles

Dipeptidyl Peptidase Inhibition Accelerates Dendritic Cell Cross Priming of Tumor-Reactive T Cells Resulting in Regression of Established Tumors

Meghaan Walsh, Aviva C Krauss, MD, Jessica PE Davis, Su Young Kim, Martin Guimond, PhD, Crystal L. Mackall, M.D., Terry J Fry, M.D.

Blood (2008) 112 (11): 2579.

https://doi.org/10.1182/blood.V112.11.2579.2579

Published: 2008

Journal Articles

Apoptosis in Response to Inhibition of Dipeptidyl Peptidase 2 (DPP2) Defines Low Risk Chronic Lymphocytic Leukemia (CLL).

Alexey V. Danilov, MD, Olga V. Danilova, PhD, Andreas K. Klein, MD, Brigitte T. Huber, PhD

Blood (2007) 110 (11): 3094.

https://doi.org/10.1182/blood.V110.11.3094.3094

Published: 2007

Journal Articles

Inhibitors of Fibroblast Activation Protein (FAP) Inhibit Primary Myeloma Growth and Osteoclastogenesis Ex Vivo and In Vivo.

Angela Pennisi, MD, Xin Li, PhD, Dana Gaddy, PhD, Nisreen Akel, Nazneen Aziz, PhD, Shmuel Yaccoby, PhD

Blood (2007) 110 (11): 813.

https://doi.org/10.1182/blood.V110.11.813.813

Published: 2007

Journal Articles

Dipeptidyl Peptidase 2 - A Pro-Survival Molecule in Chronic Lymphocytic Leukemia.

Alexey V. Danilov, MD, Olga V. Danilova, MD, Andreas K. Klein, MD, Brigitte T. Huber, PhD

Blood (2006) 108 (11): 4964.

https://doi.org/10.1182/blood.V108.11.4964.4964

Published: 2006

Journal Articles

Sulfated Colominic Acid Enhances CXCR4 Function and Promotes Hematopoietic Stem /Progenitor Egress from Bone Marrow.

Shiro Kubonishi, MD, Yoshio Katayama, MD, PhD, Shinya Yamaguchi, Hirokazu Tamamura, PhD, Nobutaka Fujii, PhD, Takeshi Watanabe, MD, PhD, Fernando Arenzana-Seisdedos, MD, Kazuma Ikeda, MD, PhD, Mitsune Tanimoto, MD, PhD

Blood (2005) 106 (11): 1390.

https://doi.org/10.1182/blood.V106.11.1390.1390

Published: 2005

Journal Articles

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.

Khuda D. Khan, MD, PhD, Susan O’Brien, MD, Kanti R. Rai, MD, Jennifer R. Brown, MD, PhD, Perry Cook, MD, Anne Marie Maddox, MD, Alison M. Duarte, MPH, Eric J. Haltom, Margaret J. Uprichard, PharmD

Blood (2005) 106 (11): 2125.

https://doi.org/10.1182/blood.V106.11.2125.2125

Published: 2005

Journal Articles

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Ayad Al-Katib, MD, David D. Hurd, MD, Robert Raju, MD, Joe Stephenson, MD, Francis Giles, MD, Eric Haltom, Margaret J. Uprichard, PharmD

Blood (2004) 104 (11): 1403.

https://doi.org/10.1182/blood.V104.11.1403.1403

Published: 2004

Journal Articles

Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells.

Yun Ge, PhD, Fenghuang Zhan, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, Guido Tricot, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD

Blood (2004) 104 (11): 634.

https://doi.org/10.1182/blood.V104.11.634.634

Published: 2004

Journal Articles

Phase 1 Rising Multiple-Dose Study of Talabostat (PT-100) in Healthy Subjects.

Margaret J. Uprichard, PharmD, Barry Jones, PhD

Blood (2004) 104 (11): 4215.

https://doi.org/10.1182/blood.V104.11.4215.4215

Published: 2004

Journal Articles

Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies

Barry Jones, Sharlene Adams, Glenn T. Miller, Michael I. Jesson, Takeshi Watanabe, Barbara P. Wallner

Blood (2003) 102 (5): 1641–1648.

https://doi.org/10.1182/blood-2003-01-0208

Published: 2003

NARROW

Bone Marrow Sinusoidal Integrity Regulates Hematopoietic Stem and Progenitor Cell Trafficking

DPP4 (CD26) Truncation Of GM-CSF and IL-3 Alters Their Signaling and Functional Activity In Normal and Leukemic Hematopoietic Stem and Progenitor Cells

Sinusoidal Endothelial CD26 Cleavage of Neuropeptide Y Regulates Transendothelial Migration and Mobilization of Hematopoietic Stem and Progenitor Cells in Response to G-CSF.

CD26 Truncation of GM-CSF and IL-3 Alters Their Functional Interactions

Dipeptidyl Peptidase Inhibition Alters Myeloid Derived Suppressor Cell Phenotype and Induces Regression of Pediatric Sarcomas.

ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL).

Differential Protein Expression of Serum in Patients with RAEB Myelodysplastic Syndromes.

Dipeptidyl Peptidase Inhibition Accelerates Dendritic Cell Cross Priming of Tumor-Reactive T Cells Resulting in Regression of Established Tumors

Apoptosis in Response to Inhibition of Dipeptidyl Peptidase 2 (DPP2) Defines Low Risk Chronic Lymphocytic Leukemia (CLL).

Inhibitors of Fibroblast Activation Protein (FAP) Inhibit Primary Myeloma Growth and Osteoclastogenesis Ex Vivo and In Vivo.

Dipeptidyl Peptidase 2 - A Pro-Survival Molecule in Chronic Lymphocytic Leukemia.

Sulfated Colominic Acid Enhances CXCR4 Function and Promotes Hematopoietic Stem /Progenitor Egress from Bone Marrow.

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells.

Phase 1 Rising Multiple-Dose Study of Talabostat (PT-100) in Healthy Subjects.

Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only